MAM
ChyronHego appoints Neil Foster as COO and CFO
MUMBAI: With an aim of continuing its global growth both organically and through acquisitions, ChyronHego’s has appointment Neil Foster as chief operating officer and chief financial officer. Foster will be based at the ChyronHego headquarters in Melville, New York reporting directly to the company’s president and CEO Johan Apel.
“We’re very privileged to welcome Neil to our senior management team as we continue to deepen and scale our operations in support of our continued expansion in global markets,” said Apel. Adding further, “With his rich experience in executive-level management at high-profile, global enterprises, Neil will play a valued leadership role in our rapidly growing company.”
Foster brings to ChyronHego more than 25 years of executive experience in various strategic, operational, financial, and corporate development roles at the nexus of media, technology, and entertainment.
“I am thrilled to join ChyronHego and Johan’s team at this exciting time in the company’s evolution,” Foster added. “With innovative products and services that empower graphics and data for the broadcast and sports industries, ChyronHego is well-positioned as a leader in one of technology’s most attractive vertical markets for software applications. I’m looking forward to applying my strategic, operational, and financial expertise to help ChyronHego create value for shareholders.”
Prior to joining ChyronHego, he served as executive vice president, operations, for Take-Two Interactive Software Inc. He has also held a number of roles in the recorded music business, including executive vice president, finance and operations, for the Columbia/Epic Label Group of Sony Music Entertainment, and co-president of Sony Music Entertainment Canada. Foster’s early career included positions at McKinsey & Company Inc. and PricewaterhouseCoopers.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
